Kuros Biosciences AG (SW:KURN) — Market Cap & Net Worth
Market Cap & Net Worth: Kuros Biosciences AG (KURN)
Kuros Biosciences AG (SW:KURN) has a market capitalization of $988.78 Million (CHF782.10 Million) as of May 2, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #9161 globally and #119 in its home market, demonstrating a -11.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kuros Biosciences AG's stock price CHF20.28 by its total outstanding shares 39175300 (39.18 Million). Review KURN liabilities breakdown to assess the company's total debt and financial obligations.
Kuros Biosciences AG Market Cap History: 2015 to 2026
Kuros Biosciences AG's market capitalization history from 2015 to 2026. Data shows change from $1.44 Billion to $1.00 Billion (-4.52% CAGR).
Kuros Biosciences AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kuros Biosciences AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.00x
Kuros Biosciences AG's market cap is 14.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.44 Billion | $6.36 Million | $6.23 Million | 226.77x | 231.43x |
| 2016 | $798.46 Million | $1.06 Million | -$19.74 Million | 752.55x | N/A |
| 2017 | $476.05 Million | $534.00K | -$16.48 Million | 891.49x | N/A |
| 2018 | $97.03 Million | $715.00K | -$11.69 Million | 135.71x | N/A |
| 2019 | $111.79 Million | $2.56 Million | -$11.25 Million | 43.65x | N/A |
| 2020 | $100.05 Million | $4.04 Million | -$11.52 Million | 24.77x | N/A |
| 2021 | $95.34 Million | $13.81 Million | -$7.54 Million | 6.90x | N/A |
| 2022 | $72.81 Million | $17.99 Million | -$14.60 Million | 4.05x | N/A |
| 2023 | $172.85 Million | $33.56 Million | -$13.73 Million | 5.15x | N/A |
| 2024 | $1.06 Billion | $75.56 Million | -$3.72 Million | 14.00x | N/A |
Competitor Companies of KURN by Market Capitalization
Companies near Kuros Biosciences AG in the global market cap rankings as of May 2, 2026.
Key companies related to Kuros Biosciences AG by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #140 globally with a market cap of $157.87 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #196 globally with a market cap of $120.60 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #234 globally with a market cap of $103.80 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #140 | Abbott Laboratories | NYSE:ABT | $157.87 Billion | $90.79 |
| #196 | Stryker Corporation | NYSE:SYK | $120.60 Billion | $315.13 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #234 | Medtronic PLC | NYSE:MDT | $103.80 Billion | $80.97 |
Kuros Biosciences AG Historical Marketcap From 2015 to 2026
Between 2015 and today, Kuros Biosciences AG's market cap moved from $1.44 Billion to $ 1.00 Billion, with a yearly change of -4.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF1.00 Billion | -26.20% |
| 2025 | CHF1.36 Billion | +28.71% |
| 2024 | CHF1.06 Billion | +511.75% |
| 2023 | CHF172.85 Million | +137.41% |
| 2022 | CHF72.81 Million | -23.64% |
| 2021 | CHF95.34 Million | -4.70% |
| 2020 | CHF100.05 Million | -10.51% |
| 2019 | CHF111.79 Million | +15.22% |
| 2018 | CHF97.03 Million | -79.62% |
| 2017 | CHF476.05 Million | -40.38% |
| 2016 | CHF798.46 Million | -44.59% |
| 2015 | CHF1.44 Billion | -- |
End of Day Market Cap According to Different Sources
On May 1st, 2026 the market cap of Kuros Biosciences AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $988.78 Million USD |
| MoneyControl | $988.78 Million USD |
| MarketWatch | $988.78 Million USD |
| marketcap.company | $988.78 Million USD |
| Reuters | $988.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technol… Read more